Drik

Drik’s in vitro toxicity assay, ADME & alternative 3D organotypic slice culture give a valuable solution to address issues of clinical relevance.

The company offers neurotoxicity studies using 3D brain models to assess CNS functional and biochemical integrity.

The page describes a computer-based modeling tool for drug candidates entering preclinical screening and mentions orthotopic xenograft and patient-derived xenograft models.

Integrated preclinical in vitro (3D model, DDI, ADME, cancer xenograft), in vivo (rodent, dog, monkey) toxicology contract service lab for Pharma, Cosmetic, Biotech & Chemical industries. Services - GLP, non-GLP.

The page describes 3D in vitro models for predicting in vivo clearance, target organ injury, and pathway characterization.

The page describes toxicity assays in slice culture as an ex vivo model between in vitro cell culture and in vivo animal studies.

Drik offers preclinical contract research organization services, including in vitro mechanistic toxicology studies.

Candidate will research toxicological data, and write risk assessments as well as provide consulting & study management.

The company conducts preclinical toxicology research and is a member of SOT and ACT.

Drik provides toxicology testing and consulting and designs studies based on clients' discovery efforts.

Drik states its commitment to the 3Rs and animal welfare, conducts ICCVAM-recommended studies, and refers to 3D organ models as animal alternatives.

Drik provides drug safety testing for nonclinical drug development and addresses efficacy questions.

Drik is a contract research laboratory focused on advancing innovations to clinical trials.

The company can conduct BSL2 studies for in vivo and in vitro toxicology testing.

Drik is a preclinical toxicology CRO that provides safety testing.